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Background: Blood or tissue culture or histology prove invasive Candida infection,
but long time to result, limited feasibility and sensitivity call for new approaches. In
this pilot project, we describe the diagnostic potential of quantitating Candida-reactive,
CD4/CD69/CD154 positive lymphocytes in blood of patients with invasive Candida
infection.
Methods: We used flow cytometry quantitating Candida-reactive, CD4/CD69/CD154
positive lymphocytes from peripheral blood of patients with invasive Candida infection,
from patients at risk and healthy volunteers as controls.
Results: Elevated levels of Candida-reactive lymphocytes were measured in 13
patients with proven invasive Candida infection and in one patient with probable
hepatosplenic candidiasis. Results of three candidemia patients were uninterpretable due
to autofluorescence of samples. Twelve of 13 patients had Candida identified to species
level by conventional methods, and T cell reactivity correctly identified Candida species
in 10 of 12 patients. Nine hematological high-risk patients and 14 healthy donors had no
elevated Candida-reactive T cell counts.
Conclusions: This Candida-reactive lymphocyte assay correctly identified the majority
of patients with invasive Candida infection and the respective species. Our assay has
the potential to support diagnosis of invasive Candida infection to species level and to
facilitate tailored treatment even when biopsies are contraindicated or cultures remain
negative.
Keywords: invasive candidiasis, candidemia, hepatosplenic candidiasis, flow cytometry, fungus-reactive T cells,
CD154
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INTRODUCTION
Invasive Candida Infection (ICI) is among the most common
bloodstream infections and represents the most common
invasive fungal infection (Wisplinghoff et al., 2004; Kullberg
and Arendrup, 2015). Candida spp. are part of the mucosal
mycobiota, and may translocate to the bloodstream. Candida
spp. may also cause complicated deep tissue disease. Organs
frequently involved are kidney, spleen, liver, central nervous
system, eyes, bones and joints (Arendrup, 2010; Kullberg and
Arendrup, 2015).
ICI is proven by direct tests, such as culture, histopathology
or direct microscopy from biopsy samples (Cuenca-Estrella et al.,
2012). Blood culture sensitivity is reported with 21–71% (Ness
et al., 1989; Kami et al., 2002). Underlying medical conditions
often prevent biopsies (Clancy and Nguyen, 2013). Indirect
tests, such as Candidamannan antigen, anti-mannan antibodies,
Candida albicans germ tube gem tube antibodies (CAGTA) and
β-1,3-D-glucan (BDG) are not species specific (Ponton et al.,
1994; Laín et al., 2007; Mikulska et al., 2010; Lamoth et al.,
2012). Polymerase chain reaction (PCR) based assays are being
evaluated, but lack validation and standardization in addition to
variable sensitivity (Schelenz et al., 2015; Pappas et al., 2016).
Fungal antigens activate CD4+ T cells, which initiate
inflammatory and antifungal immune response (Romani, 2011).
These fungal-reactive T cells are specifically directed to individual
pathogens and may promise species specificity (Bacher et al.,
2013).
We used a recently developed flow cytometry assay
quantitating Candida-reactive CD4+ T cells for ICI patients
identifying Candida to species level (Bacher et al., 2015). The
basic principle is the stimulation of patient derived CD4+ T cells
with lysates from either C. albicans, C. glabrata, C. parapsilosis,
C. tropicalis, or C. krusei. Candida-spp.-reactive CD4+ T cells
upregulate the activation markers CD154 (CD40L) and CD69,
which are detected by flow cytometry (Frentsch et al., 2005;
Bacher et al., 2013, 2014, 2015; Cossarizza et al., 2017). In a
single case report of a Candida spondylodiscitis we previously
demonstrated the benefits of the Candida-reactive lymphocyte
assay detecting ICI and Candida spp. allowing tailored treatment
(Koehler et al., 2017).
MATERIAL AND METHODS
Mechanical Lysis of Candida spp.
C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei.
were cultured for 5 days at 37◦C in Sabouraud 2% Glucose Media
(Carl Roth, Karlsruhe, Germany). Candida cells were recovered
Abbreviations: ICI, Invasive Candida Infection; CAGTA, Candida albicans Germ
Tube Antibody; BDG, β-1,3-D-glucan; PCR, Polymerase Chain Reaction; ISI,
Improving Diagnosis of Severe Infections of Immunocompromised Patients;
EDTA, Ethylenediaminetetraacetic acid; 7AAD, 7-aminoactinomycin D; SEB,
Staphylococcal Enterotoxin B; ID, Species identification; AST, Susceptibility
testing; ECMM, European Confederation of Medical Mycology; EORTC/MSG,
European Organization for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group; ROC, Receiver operating characteristic analysis;
ICU, Intensive care unit; HIV; Human immunodeficiency virus.
by centrifugation and washed with ultra-pure water (Biochrom
GmbH, Berlin, Germany). For total mycelial lysate Candida
cells were suspended in Dulbecco’s PBS (PromoCell; Heidelberg,
Germany) and lysed mechanically using gentleMACSTM M tubes
and gentleMACSTM Dissociator (both Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). Lysed mycelium of each Candida
spp. was collected by centrifugation.
By use of PierceTM BCA Protein Assay Kit (Themo Fisher
Scientific, Waltham, MA, USA) the concentration of Candida
lysates was determined.
Lysates of eachCandida spp. were stored separately in aliquots
at−80◦C.
Study Participants
Adult patients at risk were eligible to participate to the survey
per protocol – Improving Diagnosis of Severe Infections of
Immunocompromised Patients (ISI) (Identifier of the University
of Cologne Ethics Committee: 08-160). Written informed
consent was obtained from each patient or the legal guardian.
Buffy coats or peripheral ethylenediaminetetraacetic acid
(EDTA) blood samples were obtained from the Institute for
Transfusion Medicine, Klinikum Dortmund gGmbH, Germany,
the DRK Dresden, Germany, the Charité blood bank, Charité
Berlin, Germany or from in-house volunteers after informed
consent (Identifiers of the Charité Berlin Ethics Committee:
EA1/149/12; EA1/272/15).
Cell Preparation
Peripheral blood mononuclear cells (PBMC) were isolated
from EDTA blood samples by density centrifugation with
density gradient media (Axis-Shield, Oslo, Norway). PBMCs
were washed with CliniMACS PBS/EDTA buffer and RPMI-
1640 medium and were re-suspended with RPMI-1640 medium
supplemented with 5% GemcellTM human AB serum (Gemini
Bio Products, West Sacramento, CA, USA) and 1% 2mM L-
glutamin (Lonza Group, Basel, Switzerland).
Detection of Viable Cells and Culture of
PBMCs
To quantify viable cell count, PBMCs were diluted 1:10 in RPMI-
1640 medium and stained with 7-aminoactinomycin D (7AAD)
(Miltenyi Biotec GmbH and eBioscience, San Diego, CA, USA).
Data were measured with a MACSQuant R© Analyzer 10 and
MACSQuantifyTM software (Version 2.6, both Miltenyi Biotec
GmbH,) was used for evaluation. 1 × 106 cells/100 µl and well
were seeded in 100 µl RPMI-1640 medium supplemented with
5% GemcellTM human AB serum and 1% 2mM L-Glutamin into
96 well flat-bottom plates. PBMCs were incubated overnight at
37◦C with 5% CO2.
Stimulation of PBMCs
Cultured cells were stimulated with CD28 and CD40 pure
antibodies (Miltenyi Biotec GmbH) and with lysate of
C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei
or Staphylococcal Enterotoxin B (SEB) (1 µg ml−1; Sigma-
Aldrich GmbH, Munich, Germany) for 5 h at 37◦C with 5%
CO2. (Figure 1) Each Candida species was tested in separate
Frontiers in Microbiology | www.frontiersin.org 2 June 2018 | Volume 9 | Article 1381
Koehler et al. Candida-Reactive T Cells
FIGURE 1 | Concept of the Candida-reactive lymphocyte assay. Peripheral blood mononuclear cells (PBMC) are co-incubated with Candida spp. specific lysate (e.g.,
C. albicans) and stimulated with CD28 and CD40 antibodies. T cells react to the presented fungal peptides on the surface of antigen presenting cells (APC) and
upregulate the activation markers CD69 and CD154 (CD40L), which are quantified by flow cytometry after 5 h stimulation at 37◦C and 5% CO2.
stimulation. Missing challenge with fungal lysate served as
negative control, addition of SEB as positive control.
Flow Cytometry
Stimulated PBMC were stained with CD4FITC (VIT4),
CD8PerCP (BW135/80), CD14PerCP (TÜK4), CD20PerCP
(LT20), CD69APC (FN50), CD154PE (5C8) (all Miltenyi
Biotec GmbH) and 7AAD (Figure 1). Data were acquired on a
MACSQuant R© Analyzer 10 and MACSQuantifyTM software was
used for analysis. Candida-reactive CD4+ T cells were detected
based on the upregulation of CD69 and CD154 (CD40L)
(Figure 1). Gating strategy is shown in Figure 2.
Fluorescence Microscopy
For fluorescence microscopy stimulated PBMCs were stained
with CD4FITC (VIT4), CD69APC (FN50), and CD154PE (5C8)
and microscopy was performed with a Zeiss LSM Meta710
confocal microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany).
Conventional Diagnostics, Study Design
and Definitions
Blood-cultures were processed using the BactAlert 3D
(BioMerieux, Marcy l’etoile France) and the Bactec
(BectonDickinson, Franklin Lakes, NJ, USA) systems.
Identification (ID) of Candida spp. to species level and
susceptibility testing (AST) was performed using VITEK2 (ID
and AST) and API (ID, both, BioMerieux) and the MALDI
Biotyper R© (ID, Bruker Daltonics, Hilden, Germany), and E-Test
(AST, BioMerieux). BDG measurements were done using the
Fungitell ß-D-glucan ELISA assay (Associates of Cape Cod, MA,
USA). Histology was stained with Grocott methenamine silver
staining (Merck, Darmstadt, Germany and Diagonal GmbH,
Münster, Germany).
To examine the performance of Candida-reactive T cells
as diagnostic read-out for ICI, patients with proven and
suspected ICI and disease control patients were enrolled
in the web-based database of the European Confederation
of Medical Mycology (ECMM) Candida Registry CandiReg
(Identifier of the University of Cologne Ethics Committee: 17-
485, ClinicalTrials.gov Identifier: NCT03450005) (ECMM, 2018).
Risk factors, site of infection, symptoms, diagnosis, treatment and
outcome were documented.
For clinical evaluation patients cohorts were grouped
according to the 2008 European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious
DiseasesMycoses Study Group (EORTC/MSG) criteria (De Pauw
et al., 2008).
Statistical Analysis
Cut-off values discriminating between healthy donors, disease
control and patients with proven ICI were calculated by
receiver operating characteristic (ROC) analysis and p-values
were determined by Fisher’s exact test using IBM SPSS Statistics
software (Version 23, IBM Corporation, Armonk, NY, USA).
For the determination of the cut-off value of fold increase of
antigen-stimulated T cells compared to unstimulated T cells, we
excluded measurements of proven ICI patients in the presence
of antifungal treatment without elevated frequencies of Candida-
reactive T cells. To examine the cut-offs of levels of Candida-
reactive T cells discriminating between individuals with and
without ICI we excluded measurements of proven ICI patients in
the presence of antifungal treatment without elevated frequencies
of Candida-reactive T cells. Measurements of proven ICI patients
with a fold frequencies smaller than the calculated 3.05-fold
increase were excluded to exclude false-positive results and to
find correct and sufficient stimulations.
RESULTS
Patient Characteristics
We determined the performance of the Candida-reactive
lymphocyte assay in a cohort of 26 patients. Three (11.5%)
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FIGURE 2 | Flow Cytometry-Gating strategy and detection of C. glabrata-reactive T cells. Cell frequencies (%). (A) Gating strategy. Negative control, unstimulated
CD4+ T cells, show no CD69/CD154 expression. (B) Detection of C. glabrata-reactive T cells. From left to right. Negative control; positive control (staphylococcal
enterotoxin B stimulated CD4+ T cells show CD69/CD154 double-expression); antigen-stimulated probe (CD69/CD154 double expression of C. glabrata-reactive
CD4+ T cells after antigen stimulation with C. glabrata lysate).
patients were excluded from analysis due to autofluorescence
of cells leading to elevated background expression of
CD69+/CD154+ T cells. Thirteen patients (56.5%) had
proven and one patient (4.3%) probable ICI, a culture
negative hepatosplenic candidiasis (De Pauw et al., 2008).
Nine hematological high-risk patients (39.1%) served as disease
control cohort. To examine the mean frequency of C. albicans-
reactive T cells in healthy individuals we included an additional
cohort of 96 healthy blood donors.
Patient characteristics and demographic data are given in
Table 1. Most common underlying conditions of patients with
proven or probable ICI were hematological and oncological
malignancies (n= 11, 78.4%). More than half of the patients were
treated on intensive care unit (ICU) prior the diagnosis of ICI
(n = 8, 57.1%). Eight patients (57.1%) received chemotherapy
within 3 months prior the diagnosis of ICI and five patients
(35.7%) had undergone major surgery recently. Most prevalent
site of infection was the blood stream in 12 patients (85.7%).
Hepatosplenic candidiasis was found in three patients (21.4%).
Disseminated candidiasis, defined as positive blood culture
and/or at least two non-contiguous sites affected, was diagnosed
in four patients (28.6%).
Candida-Reactive T Cells in Healthy
Donors and in Disease Control Patients
In the cohort of this prospective pilot study nine disease control
patients and 14 healthy donors showed no elevated frequencies
of Candida-reactive T cells. In the cohort of 96 blood donors,
the mean frequency of C. albicans-reactive T cells was 0.19
± 0.11%. Combined frequency of C. albicans-reactive T cells
among 110 healthy donors was 0.17 ± 0.12%. Mean frequencies
of C. albicans-, C. glabrata-, C. parapsilosis-, C. tropicalis-, and
C. krusei-reactive T cells in the cohort of this prospective pilot
study were 0.07 ± 0.15%, 0.07 ± 0.14%, 0.05 ± 0.16%, 0.03 ±
0.05%, and 0.08± 0.24%, respectively.
Candida-Reactive T Cells in Patients With
Proven Invasive Candida Infection
We determined cut-off values to discriminate between healthy
donors, disease control patients and patients with ICI regarding
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TABLE 1 | Baseline characteristics of study participants.
Variables Proven and
probable ICI
(n = 14)
Disease
control
(n = 9)
AGE, YRS.
Median and SD 64.0 ± 14.1 70.0 ± 14.1
Range 33–78 34–75
BMI, kg/m2
Median and SD 22.6 ± 7.3 24.8 ± 6.8
Range 12.1–40.1 13.2–38.4
GENDER, n (%)
Female 6 (42.9) 6 (66.7)
ETHNIC ORIGIN, n (%)
Caucasian (White) 13 (92.9) 9 (100.0)
Unknown 1 (7.1)
RISK FACTORS, n (%)*
Chemotherapy 8 (57.1) 6 (66.7)
Hematopoietic stem cell
transplantation (HSCT)
3 (33.3)
Radiotherapy 2 (14.3) 1 (11.1)
Neutropenia 3 (21.4) 5 (55.6)
Surgery 5 (35.7) 2 (22.2)
UNDERLYING CONDITIONS, n (%)*
Hematological/Oncological
malignancy
11 (78.4) 8 (88.9)
HIV/AIDS 2 (14.3)
Solid organ transplantation 1 (11.1)
Rheumatic diseases/Autoimmune
disorder
1 (7.1) 2 (22.2)
Chronic cardiovascular disease 8 (57.1) 3 (33.3)
Chronic liver disease 3 (21.4)
Chronic pulmonary disease 1 (11.1)
Chronic renal disease 2 (14.3) 1 (11.1)
Diabetes mellitus 5 (35.7) 4 (44.4)
Viral pneumonia 1 (7.1) 1 (11.1)
Alcohol addiction 2 (14.3)
Obesity or underweight
†
6 (42.9) 2 (22.2)
ICU treatment 8 (57.1) 4 (44.4)
SIGNS AND SYMPTOMS, n (%)*
Fever 7 (50.0)
Chills 3 (21.4)
Tachycardia 2 (14.3)
Tachypnea 2 (14.3)
Heart failure 2 (14.3)
Hepatosplenomegaly 1 (7.1) 1 (11.1)
SITE OF INFECTION, n (%)*
Blood (culture positive) 12 (85.7)
Liver 3 (21.4)
Spleen 3 (21.4)
Peritoneum 1 (7.1)
Bones and joints 1 (7.1)
Eye 1 (7.1)
Foreign bodies 3 (21.4)
Disseminated** 4 (28.6)
AIDS, acquired immunodeficiency syndrome; BMI, body mass index; CNS, central
nervous system; HIV, human immunodeficiency virus; ICU, intensive care unit; SD,
standard deviation; * >1 factor possible per patient;
†
Obesity, BMI > 30 kg/m2,
underweight, BMI < 18.5 kg/m2; **Disseminated, positive blood culture and/or at least
two non-adjacent organs affected.
x-fold increase of Candida-reactive T cells and frequencies of
Candida-reactive T cells using ROC-analysis. Measurements
of healthy donors and disease controls were defined negative
(combined cohort of blood donors, healthy donors and disease
controls), proven invasive Candida infection was defined as
a positive test. A cut-off value of 3.05-fold increase of
antigen stimulated CD69+/CD154+ T cells compared to the
unstimulated CD4+ T cells was calculated to discriminate best
between individuals with and without ICI and to assure a
sufficient stimulation (Figure S1). Test positivity considered
elevated levels of Candida-reactive T cells with simultaneously
3.05-fold increase of antigen-stimulated T cells compared to
unstimulated T cells to exclude false-positive results. Cut-off
values for elevated levels ofC. albicans-reactive T cells were 0.40%
CD69+/CD154+ T cells among CD4+ T cells, for C. glabrata
0.22% and for C. parapsilosis 0.40%, respectively. As no patients
with invasive C. tropicalis or C. krusei infections were in our
cohort, we used the cut-off value of pooled Candida spp.-reactive
T cells of 0.40% as cut-off value for C. tropicalis and C. krusei
instead (Figure S1).
Sensitivity and Specificity of
Candida-Reactive T Cells
Candida-reactive CD4+ T cells were detected based on the
upregulation of the activation markers CD69 and CD154
(CD40L) (Figures 1, 3). We detected elevated levels of Candida-
reactive T cells in 13/16 patients (81.3%) with proven ICI. In three
patients (18.7%) with proven ICI no values could be determined
due to autofluorescence and these were excluded from this study.
In 23 individuals without ICI there were no elevated levels of
Candida-reactive T cells. The sensitivity and specificity in our
study were 81.3% and 100%, respectively (Table S1). This results
in positive and negative predictive values of 100% and 88.5%.
The correlation between elevated levels of Candida-reactive T
cells and the clinical diagnosis of proven ICI was statistically
significant with a p < 0.001 (Table S1). When excluding
autofluorescent patients from analysis sensitivity increased to
100% with a specificity of 100% (Table S2).
In 10/12 patients (83.3%) with proven ICI the Candida-
reactive lymphocyte assay identified the same Candida spp.
causing ICI as standard diagnostics (Table 2). Frequencies of
C. albicans-reactive T cells and C. glabrata-reactive T cells
in healthy donors, disease control and patients with probable
or proven ICI are given in Figure 4. In one patient with a
C. albicans candidemia and endophthalmitis we found elevated
frequencies of C. glabrata-reactive T cells instead. In another
patient with a C. albicans candidemia we measured C. albicans-
and C. parapsilosis-reactive T cells. We determined elevated
levels of C. albicans, C. glabrata, C. parapsilosis, and C. tropicalis
in a histologically proven case with hepatosplenic candidiasis
without species identification and we excluded this patient from
contingency analysis (Table 2). This leads to a sensitivity and a
specificity of the Candida-reactive lymphocyte assay identifying
ICI and the causing Candida spp. among evaluable patients with
proven ICI of 83.3 and 100%, respectively. The positive and
negative predictive values to detect ICI and the causing Candida
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FIGURE 3 | Transmitted Light—Differential Interference Contrast (DIC) and Fluorescence Microscopy of C. albicans-reactive T cells. CD4+ T cells after antigen
stimulation with C. albicans lysate and show triple positivity, CD4+/CD69+/CD154+ after stimulation. Scale bar = 10µm.
spp. by species level were 100 and 92%. The p-value was <0.001
calculated by Fisher’s exact test (Table S3).
DISCUSSION
In this pilot study, we evaluated the performance of a new
Candida-reactive lymphocyte assay as diagnostic tool for ICI.
Elevated levels of Candida-reactive CD4+ T cells were measured
based on the upregulation of the activation markers CD69 and
CD154 (CD40L) in patients with proven and probable ICI
(Frentsch et al., 2005; Bacher et al., 2013, 2014, 2015; Cossarizza
et al., 2017). Identification to species level was in agreement
with conventional diagnostics in 83.3% of proven ICI. Disease
controls and healthy controls had no elevated T cell count. In this
cohort, there was negligible cross-reactivity between the different
Candida spp. causing ICI.
The Candida-reactive lymphocyte assay compares favorable
characteristics to current gold-standard diagnostic procedures.
Volatile sensitivity ratios of blood culture are caused by
the rapid elimination of viable Candida cells from blood
circulation (Cuenca-Estrella et al., 2012; Nguyen et al., 2012;
Kullberg and Arendrup, 2015; Pappas et al., 2016). The
Candida-reactive lymphocyte assay may improve sensitivity of
and time to the diagnosis of ICI including identification of
the causative pathogen to species level and could therefore
considerably improve the treatment of patients with ICI.
However, both blood and tissue culture currently remain the
only diagnostics allowing for susceptibility testing. Microscopy,
histopathology, and culture of infectious tissue samples require
surgery or other invasive procedures with significant risks
for the patient, whereas the Candida-reactive lymphocyte
assay is a non-invasive, peripheral blood test with little to
no risks for the patient (Clancy and Nguyen, 2013).Candida
mannan antigen and antimannan antibodies, CAGTA and BDG-
measurements do not permit discrimination between different
Candida spp. and therefore in contrast to the Candida-reactive
lymphocyte assay they do not allow for definitive diagnosis and
tailored treatment (Laín et al., 2007; Kullberg and Arendrup,
2015).
As reported previously, we were able to provide flow-
cytometry based diagnostics with Candida-reactive T cells for
invasive candidiasis in a case of a patient with a human
immunodeficiency virus (HIV)-associated Burkitt lymphoma
with a C. albicans spondylodiscitis (Koehler et al., 2017). We
were able to diagnose ICI by species level, whereas in treatment
course blood culture remained negative (Table 2) (Koehler et al.,
2017). In this case, the Candida-reactive lymphocyte assay
favored conventional diagnostics due to improved sensitivity and
shortened time to diagnosis (Koehler et al., 2017).
Measuring antigen-reactive T cells by the upregulation of
the activation markers CD69 and CD154 (CD40L) can be
expanded to other pathogens with challenging diagnosis such as
Aspergillus spp. and Mucorales spp. (Bacher et al., 2013, 2014,
2015; Potenza et al., 2016; Cossarizza et al., 2017). However, it
remains unknown, how the Candida-reactive lymphocyte assay
performs when dealing with other Candida spp. causing ICI than
C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, or C. krusei.
Limitations of the Candida-reactive lymphocyte assay are
insufficient cell count of T cells or lack of antigen-presenting
cells, as well as autofluorescence of patient cells with elevated
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FIGURE 4 | Frequencies of Candida-reactive T cells in healthy donors, disease control and patients with probable or proven invasive Candida infection. Patients with
proven invasive Candida infection had a simultaneous 3.05-fold increase of antigen-stimulated T cells compared to unstimulated T cells to exclude false positive
results and to determine quality of the stimulation. Dashed lines show cut-off values for C. albicans-reactive T cells (0.40%) and C. glabrata-reactive T cells (0.22%),
respectively. Healthy donor n = 14, disease control n = 9. (A) Frequencies of C. albicans CD69+/CD154+ T cells among CD4+ T cells in donor/patient cohorts.
Given is the highest frequency during the test series. (B) Frequencies of C. glabrata CD69+/CD154+ T cells among CD4+ T cells in donor/patient cohorts. Given is
the highest frequency during the test series.
background levels of CD69 and CD154. Autofluorescence of
cells is mainly caused by dead cells, which bind antibodies in
a low-affinity and unspecific manner (Cossarizza et al., 2017).
To avoid high yields of autofluorescent cells, dead cell staining,
as well as processing and cultivation of PBMC without delay
remain mandatory (Cossarizza et al., 2017; Wurster et al.,
2017).
The performance of the Candida-reactive lymphocyte assay
may be improved by the combined determination of activation
markers and cytokines, which are typically secreted by reactive
CD4+ T cells upon activation such as interleukin-17, interleukin-
22 or interferon-γ (Potenza et al., 2016; Cossarizza et al., 2017).
With the reduction of fungal load by antimycotic treatment
or even surgery in case of invasive mold infection, we expect
the levels of fungus-reactive T cells to be decreasing over time,
which may affect the performance of the assays in patients
with extensive treatment in the past medical history, but it also
provides a simple and sensitive opportunity to follow treatment
courses of patients (Bacher et al., 2015). In our cohort, low
number of proven and probable ICI patients may hamper the
strength of the results of this pilot project so that further studies
with larger patient numbers remain mandatory also analyzing
the course of Candida-reactive T cells over the sequence of
therapy.
In summary, the Candida-reactive lymphocyte assay
may complement current diagnostics for ICI, especially
when blood cultures remain negative, as well as in cases
of underlying medical conditions with contraindication
for biopsies or surgery. The Candida-reactive lymphocyte
assay is a non-invasive, peripheral blood test and it allows
the identification of Candida spp. for targeted treatment.
As the Candida-reactive lymphocyte assay may establish
the diagnosis of ICI within 36–48 h, it may enable earlier
treatment in case of prolonged cultivation of blood
cultures.
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